Integra Lifesciences Amends Credit Agreement for Stability

Integra Lifesciences ( (IART) ) just unveiled an update.

On June 6, 2025, Integra LifeSciences amended its Credit Agreement to adjust its financial covenants, particularly increasing the maximum consolidated total leverage ratio through various fiscal quarters until March 2027. This amendment, effective during the Covenant Relief Period, also imposes temporary restrictions on investments, indebtedness, and intellectual property transactions, aiming to stabilize the company’s financial operations without increasing its total debt.

The most recent analyst rating on (IART) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.

Spark’s Take on IART Stock

According to Spark, TipRanks’ AI Analyst, IART is a Neutral.

Integra Lifesciences faces significant challenges, primarily due to profitability concerns and bearish technical indicators. The negative valuation metrics and mixed earnings call sentiment further impact the overall score. While there are some positive aspects, such as the balance sheet strength and revenue growth, these are overshadowed by operational efficiency and cash flow issues.

To see Spark’s full report on IART stock, click here.

More about Integra Lifesciences

Integra LifeSciences Holdings Corporation operates in the medical technology industry, focusing on the development and manufacturing of medical devices and implants. The company primarily serves the healthcare sector, providing products that are crucial for surgical procedures and patient care.

Average Trading Volume: 1,035,890

Technical Sentiment Signal: Sell

Current Market Cap: $1.05B

Learn more about IART stock on TipRanks’ Stock Analysis page.